Consideration about data management and biostatistics analysis from a FDA's botanical drug approval case / 中国中西医结合杂志
Chinese Journal of Integrated Traditional and Western Medicine
;
(12): 1035-1039, 2009.
Artículo
en Chino
| WPRIM
| ID: wpr-242320
ABSTRACT
FDA approved the first botanical drug of non-simplex ingredient on 31st Oct 2006. The new drug's trade name is Veregen 15% Ointment. Veregen succeeded in coming into the market in U.S, which attracts other countries and regions' attention where traditional herbs have been always used. From the viewpoints of data management and biostatistics method, the authors will think and discuss this case well, and hope to promote domestic new drug investigation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Proyectos de Investigación
/
Estados Unidos
/
United States Food and Drug Administration
/
Preparaciones Farmacéuticas
/
Bioestadística
/
Aprobación de Drogas
/
Preparaciones de Plantas
País/Región como asunto:
America del Norte
Idioma:
Chino
Revista:
Chinese Journal of Integrated Traditional and Western Medicine
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS